

6th BCOS 2025		
11th June 2025 06:00 - 09:40 PM IST		
Time	Topic	Faculty
06:00 - 06:05 PM	Welcome & Context Setting	Dr. JB Sharma, Delhi
	Session Coordinator:	Dr Abhishek Charan Jaipur
	Session 1: Lung Caner	
	Chairpersons	Dr Pawan Agarwal, Dr Lalit Mohan Sharma
06:05 - 06:25 PM	Tecentriq Plus Chemotherapy in 1L extensive - stage Small Cell Lung Cancer	Dr. Raajit Chanana, Delhi
06:25 - 06:45 PM	Treatment Dilemma: Mono Therapy Vs Combination Treatment in Advanced EGFRm NSCLC	TBD
06:45 - 07:05 PM	A New Era: Integrating Immunotherapy into LS-SCLC Management	TBD
07:05 - 07:12 PM	NEOADAUARA: OSI +/- CHEMO VS CHEMO	Dr. Stalin Bala Chowdhary, Hyderabad
07:12 - 07:19 PM	IMForte (NCT05091567)	Dr Santosh Chellapuram, Hyderabad
07:19 - 07:26 PM	#CheckMate816: Update, Ph III, Neoadjuvant Nivolumab + Chemotherapy (approved in March 2022) vs. Chemo alone in resectable non-small cell lung cancer.	Dr. Nagendra Sharma, Gurugram
07:26 - 07:33 PM	DeLLphi-304 (NCT05740566)	Dr Krishna Chaitanya, Hyderabad
07:33 - 07:53 PM	Panel Discussion on Above Abstracts	Dr Deepak Koppaka Hyderabad
		Dr Ankur Punia,Jaipur
		Dr Lalit sharma , Jaipur
		Dr Abhishek sharma Jodhpur
		Dr Priti Agarwal , Jaipur
		Dr Rohit swami, Jaipur
		Dr Jayshree Goyal Jaipur
		Dr. Vinod Sharma, Jaipur
07:53 - 07:58 PM	Expert Comment	Dr Lalit Mohan Sharma
	Session Coordinator	Dr Neha Rawat, Jaipur
	Session 2: Breast Cancer	
	Chairpersons	Dr Sandeep Jasuja , Dr Hemant Daditch
07:58 - 08:05 PM	SERENA-6 (NCT04964934)	Dr. Krupa Shankar, Bangalore
08:05 - 08:12 PM	ASCENT-04 (NCT05382286)	Dr. Ghanashyam Biswas, Bhubaneswar
08:12 - 08:19 PM	DESTINY-Breast09 (NCT04784715)	Dr. Vikas Talreja, Kanpur
08:19 - 08:40 PM	Panel Discussion	Dr. Anbarasan Sekar Mumbai
		Dr. Pankaj Goyal, Delhi
		Dr Jitender Pehaljani Jaipur

		Dr. Kunal Jain, Ludhiana
		Dr. Sajjan Rajpurohit, Delhi
		Dr. Vikas Asati, Indore
		Dr. K Medhi, Gurugram
		Dr. Parmod Pal, Jodhpur
08:40 - 08:45 PM	Expert Comment	Dr. Sandeep Jasuja, Jaipur
08:45 - 09:05 PM	Transform the Journey for your HER2+ Breast Cancer Patients	Dr. Siddharth Kumar Sahai, Delhi
09:05 - 09:25 PM	Trastuzumab Deruxtecan for the treatment of HR+/HER2 low mBC and HR+/HER2 ultralow mBC	Dr. Abhishek Anand, Patna
09:25 - 09:40 PM	Quiz	Dr. Neha Rawat
09:40 PM Onwards	Closing Remarks	

6th BCOS 2025		
12th June 2025 06:00 - 09:10 PM IST		
Time	Topic	Faculty
06:00 - 06:05 PM	Welcome & Context Setting	Dr. Naresh Somani, Jaipur
	Session Coordinator:	Dr. Mansi Shah, Udaipur
	Chairpersons:	Dr. Jitendra Pehalajani, Jaipur Dr. Divesh Goyal, Jaipur
	Industry Sponsored Session	
06:05 - 06:45 PM	Selecting appropriate Frontline Immunotherapybased treatment in RCC	
	Moderator:	Dr. Dipanjan Panda, Delhi
	Panelists:	Dr. K Medhi, Gurugram
		Dr. Javvid Muzamil, Srinagar
		Dr. K M Parthasarathy, Delhi
		Dr. Yuganshu Gupta, Ambala
	Session 1: GI Cancer	
06:45 - 06:52 PM	#Plenary Session: #ATOMIC Ph III, Adj FOLFOX vs. Atezolizumab + FOLFOX for dMMR Stage III resected colon cancer.	Dr. Sumit Goyal, Delhi
06:52 - 06:59 PM	#Plenary Session: #MATTERHORN Ph III, PeriOp Durvalumab + FLOT (and postOP Durva + FLOT Durva) vs PeriOP and PostOP FLOT for resectable gastric/gastroesophageal junction cancer.	Dr. M V Chandrakanth, Kolkata
06:59 - 07:06 PM	LEAP-002 long-term follow-up: Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma.	Dr. Satyanker Gupta, Jammu
07:06 - 07:13 PM	CheckMate 577 (NCT02743494; OS Update)	Dr. Jagdeep Singh, Amritsar
07:13 - 07:40 PM	Panel Discussion on Above Abstracts	Dr. Prabhat Bhargava, Mumbai
		Dr. Gunjan Shrivastava, Gwalior
		Dr. BS Ankit Nehra, Jaipur
		Dr. Aditi Mittal, Jaipur
		Dr. Ananya Pareek, Jaipur
		Dr. Tarachand Gupta, Jaipur

07:40 - 07:45 PM	Expert Comment:	Dr. Jitendra Pehalajani, Jaipur
07:45 - 08:05 PM	Transforming Patient Outcomes with Newer Innovative therapies in 1L Advanced HCC_How IO+IO Regimen (STRIDE) reshaping the Treatment Landscape	Dr. Chandragouda D, Delhi
	Session Coordinator:	Dr. Rahul Rai, Bikaner
	Session 2: GU Cancer	
	Chairpersons:	Dr. Surendra Beniwal, Bikaner Dr. S P Kataria, Gurugram
08:05 - 08:12 PM	Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC).	Dr. (Lt. Col.) Brahmajit Singh, Ghaziabad
08:12 - 08:19 PM	SURE-02 (NCT05535218) Phase 2, open-label, non-randomized study investigating neoadjuvant sacituzumab govitecan plus pembrolizumab followed by response-adapted bladder sparing and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer (MIBC)	Dr. Varun Goel, Delhi
08:19 - 08:26 PM	#NIAGARA: Ph III, use of ctDNA in patients who received periOP durvalumab (PeriOp/PostOp Durvalumab got approved in March 2025) muscle-invasive bladder cancer.	Dr. Mridul Malhotra, Delhi
08:26 - 08:50 PM	Panel Discussion on Above Abstracts	Dr. Akhil Kapoor, Varanasi Dr. Deepak Shukla, Jaipur Dr. Aseem Samar, Jaipur Dr. Pulkit Nag, Jaipur Dr. Sudhir Palsaniya, Jaipur Dr. Ankit Agarwal, Udaipur Dr. Rahul Rai, Bikaner
08:50 - 08:55 PM	Expert Comment:	Dr. S P Kataria, Gurugram
08:55 - 09:10 PM	Quiz for Residents	TBD
09:10 PM Onwards	Closing Remarks	